- Home
- MNSB vs MIST Comparison
MNSB vs MIST Comparison
Compare MNSB & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MNSB | MIST |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | Canada |
| Employees | 171 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 172.3M | 176.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MNSB | MIST |
|---|---|---|
| Price | $24.81 | $1.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 54.8K | ★ 2.6M |
| Earning Date | 04-20-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.62% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.50 | $2,915.14 |
| Revenue Next Year | $3.77 | N/A |
| P/E Ratio | $12.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.86 | $1.00 |
| 52 Week High | $25.17 | $3.06 |
Technical Indicators
Market Signals| Indicator | MNSB | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 65.79 | 51.62 |
| Support Level | $20.84 | $1.66 |
| Resistance Level | $25.14 | $2.01 |
| Average True Range (ATR) | 0.71 | 0.14 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 66.67 | 3.85 |
Price Performance
Historical ComparisonAbout MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).